Abstract
A highly sensitive ultra-high pressure liquid chromatography (UHPLC-MS/MS) method for estimation of paclitaxel in rat plasma has been validated. The chromatographic separation was achieved using isocratic mobile phase, consisting of acetonitrile–2mM ammonium acetate (70:30 v/v; 0.25 mL min-1). Docetaxel was used as an internal standard and tert-butyl methyl ether (TBME) as organic solvent for the liquid-liquid extraction. The mass spectrometer was operated in synapt mass spectrometry mode via positive electrospray ionization using the transitions m/z 854.4 → 286.1for paclitaxel, and m/z 808.3→ 527.2 as a parent ion of docetaxel (IS). The mean extraction-efficiency of QC samples was 90%. The lower limit of quantification (LLOQ) was 1.0 ng/mL. This method covered a linearity range from 1- 5000 ng/ml, with the total run time of 3.0 min. The applicability of UHPLC-MS/MS method was demonstrated and successfully applied for pharmacokinetic profiling of paclitaxel in rat plasma after oral administration.
Keywords: Paclitaxel, docetaxel, liquid-liquid extraction, tert-butyl methyl ether, oral administration, pharmacokinetic study.
Graphical Abstract
Current Bioactive Compounds
Title:Pharmacokinetic Analysis of Taxane Through a Validated Ultra-High Performance Liquid Chromatography-Synapt Mass Spectrometry (UHPLC-MS/MS ESI-Q-TOF) Method
Volume: 12 Issue: 2
Author(s): Javed Ahmad, Niyaz Ahmad, Kanchan Kohli, Showkat R. Mir and Saima Amin
Affiliation:
Keywords: Paclitaxel, docetaxel, liquid-liquid extraction, tert-butyl methyl ether, oral administration, pharmacokinetic study.
Abstract: A highly sensitive ultra-high pressure liquid chromatography (UHPLC-MS/MS) method for estimation of paclitaxel in rat plasma has been validated. The chromatographic separation was achieved using isocratic mobile phase, consisting of acetonitrile–2mM ammonium acetate (70:30 v/v; 0.25 mL min-1). Docetaxel was used as an internal standard and tert-butyl methyl ether (TBME) as organic solvent for the liquid-liquid extraction. The mass spectrometer was operated in synapt mass spectrometry mode via positive electrospray ionization using the transitions m/z 854.4 → 286.1for paclitaxel, and m/z 808.3→ 527.2 as a parent ion of docetaxel (IS). The mean extraction-efficiency of QC samples was 90%. The lower limit of quantification (LLOQ) was 1.0 ng/mL. This method covered a linearity range from 1- 5000 ng/ml, with the total run time of 3.0 min. The applicability of UHPLC-MS/MS method was demonstrated and successfully applied for pharmacokinetic profiling of paclitaxel in rat plasma after oral administration.
Export Options
About this article
Cite this article as:
Ahmad Javed, Ahmad Niyaz, Kohli Kanchan, R. Mir Showkat and Amin Saima, Pharmacokinetic Analysis of Taxane Through a Validated Ultra-High Performance Liquid Chromatography-Synapt Mass Spectrometry (UHPLC-MS/MS ESI-Q-TOF) Method, Current Bioactive Compounds 2016; 12 (2) . https://dx.doi.org/10.2174/157340721202160504222440
DOI https://dx.doi.org/10.2174/157340721202160504222440 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Development of Pro-Apoptotic Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry Clinical Significance of Breast Cancer Resistance Protein/ABCG2 in the Management of Malignancy
Clinical Cancer Drugs METCAM/MUC18 Expression and Cancer Metastasis
Current Genomics Biopharmaceutics and Therapeutic Potential of Engineered Nanomaterials
Current Drug Metabolism Tuberculosis Treated by Multiple Drugs: An Overview
Current Drug Delivery Pharmacometrics of Stilbenes: Seguing Towards the Clinic
Current Clinical Pharmacology Developing FGFR4 Inhibitors As Potential Anti-Cancer Agents Via In Silico Design, Supported by In Vitro and Cell-Based Testing
Current Medicinal Chemistry Epigallocatechin-3-gallate(EGCG): Mechanisms and the Combined Applications
Combinatorial Chemistry & High Throughput Screening Porphyrins as Radiosensitizing Agents for Solid Neoplasms
Current Pharmaceutical Design The Endocannabinoid System: A Promising Target for the Management of Type 2 Diabetes
Current Protein & Peptide Science Oxycodone/Naloxone in the Management of Patients with Pain and Opioid–Induced Bowel Dysfunction
Current Drug Targets Advances in Nanomaterials for Diagnosis and Therapy of Leukemia
Recent Patents on Nanomedicine SELDI Protein Chip Technology for the Detection of Serum Biomarkers for Liver Disease
Protein & Peptide Letters Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder
Current Neuropharmacology Targeting Vascular Changes in Lesions in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Central Nervous System Agents in Medicinal Chemistry Anti-EGFR-mAb and 5-Fluorouracil Conjugated Polymeric Nanoparticles for Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology Recent Patents on Genes and Gene Sequences Useful for Developing Breast Cancer Detection Systems
Recent Patents on DNA & Gene Sequences Role of Advanced Glycation End Products in Diabetic Neuropathy
Current Pharmaceutical Design Causal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving Surgery*
Recent Patents on Anti-Cancer Drug Discovery